WealthPLAN Partners LLC Raises Stock Position in Johnson & Johnson (NYSE:JNJ)

WealthPLAN Partners LLC grew its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 7.4% during the first quarter, HoldingsChannel.com reports. The fund owned 109,796 shares of the company’s stock after purchasing an additional 7,562 shares during the quarter. Johnson & Johnson makes up about 1.4% of WealthPLAN Partners LLC’s portfolio, making the stock its 11th biggest holding. WealthPLAN Partners LLC’s holdings in Johnson & Johnson were worth $19,814,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in JNJ. Norges Bank acquired a new stake in Johnson & Johnson during the 4th quarter valued at $4,172,929,000. BlackRock Inc. grew its holdings in Johnson & Johnson by 2.6% during the 4th quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock valued at $34,217,654,000 after purchasing an additional 4,982,885 shares in the last quarter. GQG Partners LLC grew its holdings in Johnson & Johnson by 1,109.4% during the 4th quarter. GQG Partners LLC now owns 3,954,383 shares of the company’s stock valued at $676,375,000 after purchasing an additional 3,627,424 shares in the last quarter. State Street Corp grew its holdings in Johnson & Johnson by 1.8% during the 4th quarter. State Street Corp now owns 144,677,639 shares of the company’s stock valued at $24,750,004,000 after purchasing an additional 2,492,359 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Johnson & Johnson by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company’s stock valued at $7,576,867,000 after purchasing an additional 1,084,834 shares in the last quarter. 68.78% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In related news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,785,140. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,785,140. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares in the company, valued at $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.

Analysts Set New Price Targets

JNJ has been the subject of several recent analyst reports. SVB Leerink decreased their price objective on shares of Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Daiwa Capital Markets initiated coverage on shares of Johnson & Johnson in a report on Wednesday, June 22nd. They set an “outperform” rating for the company. The Goldman Sachs Group raised their price objective on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a report on Tuesday, April 12th. Finally, Raymond James raised their price objective on shares of Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $189.89.

Johnson & Johnson Trading Down 0.3 %

Johnson & Johnson stock opened at $173.91 on Tuesday. The firm’s 50-day moving average is $175.84 and its 200-day moving average is $174.50. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The company has a market cap of $457.63 billion, a P/E ratio of 25.31, a PEG ratio of 3.32 and a beta of 0.59.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. The firm had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. Johnson & Johnson’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period last year, the firm posted $2.48 EPS. On average, equities analysts expect that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be given a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.60%. Johnson & Johnson’s dividend payout ratio is presently 65.79%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.